{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fidpodcast.simplecast.com%2Fepisodes%2Fnext-up-in-pbc-podcast-updates-from-easl-2026-Vs0pPIwX","width":444,"version":"1.0","type":"rich","title":"Next Up in PBC Podcast: Updates From EASL 2026","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/003a9e73-e59c-4792-897b-7bcddf17cb96/101354_next_up_pbc_me3000x3000.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/dbbf20b5-2214-4d4f-8689-4709a61f53cc\" height=\"200\" width=\"100%\" title=\"Next Up in PBC Podcast: Updates From EASL 2026\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"At the 2026 EASL Congress, a growing body of evidence suggested that the effectiveness of PBC treatment with PPAR agonists was consistent with that reported in phase III studies. Hear about the implications of these and other recent data from expert faculty Maria Londoño, MD, PhD."}